GR1002776B - Εξουδετερωση της αντιπηκτικης δρασης του συμπλεγματος της αντιθρομβινης-ιιι/ ηπαρινης, νεα δοκιμασια αποκαλυψης θρομβοφιλικων καταστασεων - Google Patents
Εξουδετερωση της αντιπηκτικης δρασης του συμπλεγματος της αντιθρομβινης-ιιι/ ηπαρινης, νεα δοκιμασια αποκαλυψης θρομβοφιλικων καταστασεωνInfo
- Publication number
- GR1002776B GR1002776B GR960100411A GR960100411A GR1002776B GR 1002776 B GR1002776 B GR 1002776B GR 960100411 A GR960100411 A GR 960100411A GR 960100411 A GR960100411 A GR 960100411A GR 1002776 B GR1002776 B GR 1002776B
- Authority
- GR
- Greece
- Prior art keywords
- heparin
- ratio
- abnormal
- attiii
- factor
- Prior art date
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002897 heparin Drugs 0.000 title abstract 3
- 229920000669 heparin Polymers 0.000 title abstract 3
- 230000003558 thrombophilic effect Effects 0.000 title abstract 2
- 230000002429 anti-coagulating effect Effects 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 206010053567 Coagulopathies Diseases 0.000 abstract 2
- 230000035602 clotting Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 108090000935 Antithrombin III Proteins 0.000 abstract 1
- 102100022977 Antithrombin-III Human genes 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 108010014172 Factor V Proteins 0.000 abstract 1
- 206010058279 Factor V Leiden mutation Diseases 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 206010059598 Heparin resistance Diseases 0.000 abstract 1
- 206010020608 Hypercoagulation Diseases 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000005665 thrombophilia Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR96100411 | 1996-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1002776B true GR1002776B (el) | 1997-09-26 |
Family
ID=10942565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR960100411A GR1002776B (el) | 1996-12-02 | 1996-12-02 | Εξουδετερωση της αντιπηκτικης δρασης του συμπλεγματος της αντιθρομβινης-ιιι/ ηπαρινης, νεα δοκιμασια αποκαλυψης θρομβοφιλικων καταστασεων |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1002776B (el) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2583881A1 (fr) * | 1985-06-21 | 1986-12-26 | Girolami Antoine | Procede et solution pour determiner les temps de howell et realiser les tests de tolerance a l'heparine |
| EP0217768A2 (en) * | 1985-09-05 | 1987-04-08 | E. Thye Yin | Method and compositions for heparin assays |
| WO1990011368A1 (en) * | 1989-03-21 | 1990-10-04 | Proksch Gary J | Factor sensitive reagent for testing of blood coagulation |
| WO1991001383A1 (en) * | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
| EP0570356A1 (de) * | 1992-05-15 | 1993-11-18 | IMMUNO Aktiengesellschaft | Reagens zur Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT) |
| WO1995012817A1 (en) * | 1992-06-08 | 1995-05-11 | Research Corporation Technologies, Inc. | Method for measuring heparin |
-
1996
- 1996-12-02 GR GR960100411A patent/GR1002776B/el unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2583881A1 (fr) * | 1985-06-21 | 1986-12-26 | Girolami Antoine | Procede et solution pour determiner les temps de howell et realiser les tests de tolerance a l'heparine |
| EP0217768A2 (en) * | 1985-09-05 | 1987-04-08 | E. Thye Yin | Method and compositions for heparin assays |
| WO1990011368A1 (en) * | 1989-03-21 | 1990-10-04 | Proksch Gary J | Factor sensitive reagent for testing of blood coagulation |
| WO1991001383A1 (en) * | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
| EP0570356A1 (de) * | 1992-05-15 | 1993-11-18 | IMMUNO Aktiengesellschaft | Reagens zur Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT) |
| WO1995012817A1 (en) * | 1992-06-08 | 1995-05-11 | Research Corporation Technologies, Inc. | Method for measuring heparin |
Non-Patent Citations (1)
| Title |
|---|
| J. FAREED ET AL.: "New perspectives in coagulation testing.", CLINICAL CHEMISTRY., vol. 26, no. 10, September 1980 (1980-09-01), WINSTON US, pages 1380 - 1391, XP002037089 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gosselin et al. | A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods | |
| Friedman et al. | A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients | |
| Varadi et al. | Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation | |
| Takahashi | Studies on the pathophysiology and treatment of von Willebrand's disease. IV. Mechanism of increased ristocetin-induced platelet aggregation in von Willebrand's disease | |
| Halbmayer et al. | Influence of lupus anticoagulant on a commercially available kit for APC-resistance | |
| Forastiero et al. | Evaluation of recently described tests for detection of the lupus anticoagulant | |
| Nicolaes et al. | A prothrombinase-based assay for detection of resistance to activated protein C | |
| Nyman | Von Willebrand factor dependent platelet aggregation and adsorption of factor VIII related antigen by collagen | |
| Tosetto et al. | Diagnosis of APC resistance in patients on oral anticoagulant therapy | |
| Lalloo et al. | Coagulopathy following bites by the Papuan taipan (Oxyuranus scutellatus canni) | |
| GR1002776B (el) | Εξουδετερωση της αντιπηκτικης δρασης του συμπλεγματος της αντιθρομβινης-ιιι/ ηπαρινης, νεα δοκιμασια αποκαλυψης θρομβοφιλικων καταστασεων | |
| Scully et al. | An acquired coagulation inhibitor to factor II | |
| Kindness et al. | Effect of polyanetholesulphonic acid and xylan sulphate on antithrombin III activity | |
| De Mitrio et al. | Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation | |
| Brien et al. | Discrepant results in INR testing | |
| Leroy-Matheron et al. | Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1+ 2, thrombin-antithrombin complexes and D-dimers) measurements | |
| US6051434A (en) | Activated protein C resistance test | |
| Tripodi et al. | Performance of quantitative D‐dimer methods: results of the Italian external quality assessment scheme | |
| Caron et al. | A blinded in vitro study with Refacto® mock plasma samples: similar FVIII results between the chromogenic assay and a one‐stage assay when using a higher cephalin dilution | |
| TAKAHASHI et al. | Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders | |
| Hemker et al. | Determination of the Levels of Unfractionated and Low-Molecular-Weight Heparins in Plasma: Their Effect on Thrombin-Mediated Feedback Reactions in vivo: Preliminary Results after Subcutaneous Injection | |
| Usher et al. | A comparison of Lp (a) levels in fresh and frozen plasma using ELISAs with either anti-apo (a) or anti-apoB reporting antibodies | |
| De Stefano et al. | Transient ischemic attack in a patient with congenital protein‐c deficiency during treatment with stanozolol | |
| Andreasen | Automated two-stage assay for determination of antithrombin III with a centrifugal analyzer | |
| Wolf et al. | Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin |